A clinical trial finder for Alzheimer’s is a searchable database or tool that connects people with neurodegenerative disease to ongoing research studies testing new treatments. The most widely used platform is ClinicalTrials.gov, operated by the National Library of Medicine, which lists over 14,000 active Alzheimer’s trials worldwide. However, the existence of these trials does not mean most people can actually access them—geographic distance, strict enrollment criteria, transportation costs, and long waitlists create barriers that eliminate the majority of interested participants before they ever begin.
For example, a person living in rural Arkansas searching for an early-stage preventive trial for cognitive decline might find seven trials listed nationally on ClinicalTrials.gov, but when filtering for trials within 100 miles, the results drop to zero. Trial finders are genuinely useful tools for understanding what research is underway and what experimental treatments exist. But they are not equal to a pathway to treatment, and treating them as a solution to Alzheimer’s overlooks the structural gaps between what trials exist and who can realistically join them. This article examines what trial finders can tell you, what they cannot, and how to navigate their limitations.
Table of Contents
- How Clinical Trial Finders Work and What Data They Contain
- What the Published Evidence Shows About Alzheimer’s Trial Success Rates
- Enrollment Barriers That Trial Finders Don’t Disclose
- Geographic Availability and the “Trial Desert” Problem
- How to Distinguish Between Phases and Recognize Red Flags in Recruitment
- Comparing Trial Finders: NIH ClinicalTrials.gov Versus Private and Institutional Databases
- What Happens After a Trial Ends: The Access and Continuation Problem
- Frequently Asked Questions
How Clinical Trial Finders Work and What Data They Contain
Clinical trial finders operate by aggregating publicly available trial registration information submitted by researchers, institutions, and pharmaceutical companies. When a trial is designed and funded, the sponsors are required by law to register it on ClinicalTrials.gov before enrollment begins. The database records the trial phase (Phase 1 through Phase 4), the condition being studied, inclusion and exclusion criteria, the study location, contact information, and expected enrollment dates. Search filters allow users to narrow results by location, study type, age, and disease stage. The information provided is generally accurate but incomplete in ways that matter.
ClinicalTrials.gov will tell you that a trial is recruiting, but not how quickly slots are filling or how long the actual wait to enroll is once you contact the site. A trial listed as “active, not recruiting” may be moving toward results, or it may have encountered enrollment problems and shifted focus. Descriptions of experimental medications are usually straightforward for double-blinded trials, but companies sometimes describe mechanisms in vague terms—”supports neuroinflammatory pathway modulation” can mean many different things, and the finder provides no interpretation. A trial listed for Boston might have satellite sites in Rhode Island and Connecticut, or it might not; the database doesn’t always specify where actual enrollment happens. These gaps mean that using a trial finder is a starting point, not a complete picture.
What the Published Evidence Shows About Alzheimer’s Trial Success Rates
The evidence on clinical trial outcomes in Alzheimer’s research reveals a sobering reality: even trials that reach completion and publication often show modest or limited benefit. Of the roughly 150 to 200 Alzheimer’s trials that complete enrollment each year globally, fewer than 15 percent result in drugs approved by the FDA or EMA. Many trials do show statistically significant slowing of cognitive decline, but the clinical meaning is disputed—a drug that slows decline by 25 percent over 18 months delays symptoms by roughly 4 to 6 months on average, not by years. The population-level benefit is real for public health, but the individual participant may experience a delay so subtle that it goes unnoticed against the background of normal disease variability. High-profile failures illustrate the gap between biological promise and real-world results.
Solanezumab, backed by Eli Lilly and tested in multiple large Phase 3 trials, reduced amyloid plaques in the brain and showed optimistic early signals but failed to meet cognitive benefit endpoints in 2013. Aducanumab, approved by the FDA in 2021 after controversy and later withdrawn from the market in 2023, produced both enthusiasm and skepticism about how meaningful trial results should be measured. Amyloid-targeting drugs that did succeed, like lecanemab (Leqembi) and donanemab, showed 25 to 35 percent slowing of decline in early-stage disease, which is meaningful but not transformative. Trial finders cannot tell you these histories or help you distinguish between preliminary Phase 2 data (often optimistic) and completed Phase 3 data (more realistic). A person browsing trials might see three early-stage amyloid monoclonal antibodies and assume rapid progress, when in fact only one or two of dozens attempted in the past decade ever reached approval.
Enrollment Barriers That Trial Finders Don’t Disclose
Trial finders list inclusion criteria, but what they don’t show is how aggressively those criteria are enforced in practice and how they eliminate the majority of people who apply. An Alzheimer’s trial might list “age 50–85” and “mild cognitive impairment or mild dementia,” which sounds broadly applicable. But the fine print often includes requirements like “amyloid positivity confirmed by PET scan or CSF biomarker,” “caregiver availability for weekly clinic visits,” “absence of significant vascular disease on MRI,” “no recent antipsychotic use,” and “MMSE score between 20 and 26.” When applied together, these criteria exclude approximately 40 to 60 percent of people with mild cognitive impairment who inquire, and a further 20 percent of those who initially qualify due to discoveries made during baseline testing. Transportation and logistics are invisible barriers that trial finders do not capture. A Phase 3 trial might require clinic visits every 4 weeks for 18 months, meaning 18 in-person appointments 90 miles away.
A person without a caregiver able to drive, or without reliable transportation, cannot participate even if medically eligible. Some trials, particularly those run by pharmaceutical companies at for-profit research centers, offer travel reimbursement; others do not. Site selection is driven by research economics, not participant convenience, so trials cluster in university towns and major cities. In rural regions, the nearest site might be 200 miles away, and the trial finder gives no indication of this practical impossibility until contact is made. Investigators also rarely advertise that enrollment has been slow or that wait lists have developed, so a person might spend weeks preparing, arrange time off work, and drive to the site only to learn that the trial is no longer enrolling or has a six-month queue.
Geographic Availability and the “Trial Desert” Problem
Trial finders use zip code or radius searches to help locate nearby sites, but availability varies wildly by region. A search for “Alzheimer’s clinical trials” near Boston returns 47 active trials with multiple enrollment sites. The same search near Boise, Idaho returns 3 trials, one of which is recruiting only for family members of participants, not for affected individuals. In parts of the rural South, Midwest, and Mountain West, there are often zero active trials within a reasonable travel distance.
This disparity means that access to cutting-edge treatments is strongly determined by geography, not medical need or willingness to participate. The trial-dense regions tend to be wealthy, urban, and home to major research universities and medical centers. Participants in these regions skew toward higher education, higher income, and whiter demographics, which means that the research data emerging from these trials may not generalize well to the broader population. Diversity in clinical trial enrollment for Alzheimer’s is a long-standing concern; Black and Hispanic participants make up roughly 8 to 12 percent of major Alzheimer’s trials, compared to 25 to 30 percent prevalence in the disease population. A trial finder in Sacramento, California might match a person with three nearby sites, while an equally motivated person in rural Louisiana has no options, so the tool’s apparent universality masks profound inequality in access.
How to Distinguish Between Phases and Recognize Red Flags in Recruitment
Clinical trial phases have specific meanings, and trial finders should make this clear but often don’t, or bury it in small text. Phase 1 trials are primarily safety and dosage studies, usually with 20 to 100 healthy volunteers or people with the disease; they are not designed to prove efficacy and rarely include people outside the immediate research site. Phase 2 trials introduce efficacy measurement and expand to 100 to 300 participants; promising Phase 2 results often don’t replicate in Phase 3. Phase 3 trials are the definitive test, typically involving 1,000 to 5,000 participants across multiple sites; only Phase 3 success typically leads to regulatory approval.
A person reading trial descriptions might see “Phase 2 study of BioMed-447 shows promising early results” and assume approval is imminent, when in reality 60 to 70 percent of Phase 2 trials fail in Phase 3. Red flags in trial recruitment messaging include claims that a trial has a “cure” or “breakthrough” potential, promises of extended access to medication after the trial ends without legal language specifying how long or under what cost, emphasis on personal testimonials rather than data, and vague descriptions of mechanism of action. Trial finders themselves don’t evaluate recruitment materials, so a professional-looking website advertising a trial does not mean the trial is legitimate or the claims are accurate. Participants should verify that the sponsoring institution is a recognized medical center or that the trial appears in peer-reviewed literature when recruitment emphasizes results. If the trial name and protocol do not appear in ClinicalTrials.gov and in PubMed, that is a warning sign.
Comparing Trial Finders: NIH ClinicalTrials.gov Versus Private and Institutional Databases
ClinicalTrials.gov is the government standard and includes most regulated trials in the United States, but it is not exhaustive. Purely academic research not funded by NIH or requiring FDA oversight may not be registered, and international trials outside U.S. regulatory jurisdiction are sometimes absent or listed in varying detail. Private clinical trial matching services exist—sites like TrialMatch.com, CenterWatch, and ResearchMatch offer filters and matching algorithms, but these are typically funded by pharmaceutical companies or research organizations and may preferentially list studies that pay for inclusion.
Institutional trial finders run by major medical centers (Mayo Clinic, Cleveland Clinic, Dana-Farber) provide more detail about their own trials but do not include trials at competing institutions. The practical difference is that ClinicalTrials.gov is free, comprehensive, and not biased toward any commercial interest, but it requires more work to interpret. Private services offer convenience and sometimes better filtering by demographics or specific biomarkers, but they may not be complete and their data depends on sponsors choosing to list. A person searching for a trial should start with ClinicalTrials.gov, then cross-reference with institutional sites for any major research center nearby, and use private services only as a supplementary check. None of these databases track whether a trial is actually enrolling at full capacity or has quietly stalled.
What Happens After a Trial Ends: The Access and Continuation Problem
Clinical trial finders are focused on current recruitment, but they do not address what happens when a trial concludes. If a trial successfully demonstrates that a drug slows cognitive decline, participants may face an abrupt discontinuation of the experimental medication unless the company offers an extended-access program or provides a transition plan to a commercial formulation. Some companies commit to post-trial access for participants, but this commitment is voluntary and not guaranteed. Participants in negative trials—those that fail to meet efficacy endpoints—typically have no option to continue the drug and must stop immediately.
The experience of participants in the lecanemab trials illustrates this reality. When trials concluded and the drug was approved for market use, access depended on insurance coverage and ability to pay out-of-pocket costs ($26,500 per year for infusions). Trial participants who were uninsured or lived in states where Medicaid did not immediately cover the drug faced a gap. Some participants in earlier-phase lecanemab trials ended up worse off after enrollment concluded than they would have been had they not participated—they had experienced several months of monthly clinic visits and infusions, then lost access entirely when their insurance denied coverage. Trial finders make participation sound like direct access to innovation, but the financial and medical safety net stops the moment the trial ends or the participant is no longer eligible.
Frequently Asked Questions
Is it worth joining an Alzheimer’s clinical trial if I’m only mildly affected?
Early-stage trials testing preventive approaches or slowing decline do focus on mild cognitive impairment and early dementia. The benefit is modest (typically 4 to 6 months of delay), the time commitment is substantial (clinic visits every 4 weeks for 12 to 24 months), and the drug remains experimental. The decision depends on your geographic proximity to a site, willingness to absorb travel costs, and personal tolerance for uncertainty about benefit. If you are comfortable with the logistics and the modest expected benefit, early enrollment gives the longest window to observe whether the drug actually helps you.
Should I trust Phase 2 trial results listed on ClinicalTrials.gov?
Phase 2 trials are designed to measure safety and preliminary efficacy, and positive results should not be misinterpreted as proven benefit. Roughly 60 to 70 percent of drugs that show promise in Phase 2 fail in Phase 3. Phase 2 data justifies moving forward with research, but it is not equivalent to proof that the drug will help. If a trial description emphasizes Phase 2 results without mentioning Phase 3 status, assume the drug is still unproven.
Are trials in wealthy neighborhoods more advanced than trials elsewhere?
Trials are distributed based on research funding and institutional infrastructure, not on whether participants in one region are sicker or more motivated. Urban centers with major research hospitals will have more active trials, and that affects what options are available. It does not mean those trials are more advanced; it means access is unequal. A person in San Francisco and a person in rural Mississippi might both benefit from the same experimental drug, but only the San Francisco participant has geographic access to test it.
What should I ask the trial coordinator when I inquire about enrollment?
Ask the current enrollment status (truly recruiting, or a wait list?), exact location of clinic visits and whether satellite sites exist closer to your home, transportation reimbursement and how it is calculated, what happens to medications after the trial ends, and withdrawal procedures if you decide the time commitment is not sustainable. Ask for a written copy of the informed consent form before committing, and review it carefully. Do not let time pressure or hope for miraculous benefit override practical concerns about logistics.
What’s the difference between a trial sponsored by a pharmaceutical company and one sponsored by an academic institution?
Pharma-sponsored trials are typically larger, better-funded, and conducted by professional clinical research organizations with experience in multi-site coordination. They are also more likely to have strict timelines and may discontinue participants who don’t meet protocol precisely. Academic trials are often smaller, more flexible in their protocols, and closer to the researcher’s own work, but enrollment can be slower and sites may be limited. Neither type is inherently superior; it depends on the specific trial. Both should be registered on ClinicalTrials.gov and have IRB oversight.
